UroGen Total Cash From Financing Activities from 2010 to 2024
| URGN Stock | USD 12.66 0.18 1.44% |
Total Cash From Financing Activities | First Reported 2014-12-31 | Previous Quarter 100.3 M | Current Value 39.6 M | Quarterly Volatility 38.2 M |
Check UroGen Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among UroGen Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 966.1 K, Interest Expense of 15.5 M or Selling General Administrative of 94.9 M, as well as many indicators such as Price To Sales Ratio of 4.97, Dividend Yield of 0.0 or Days Sales Outstanding of 98.77. UroGen financial statements analysis is a perfect complement when working with UroGen Pharma Valuation or Volatility modules.
UroGen | Total Cash From Financing Activities |
Latest UroGen Pharma's Total Cash From Financing Activities Growth Pattern
Below is the plot of the Total Cash From Financing Activities of UroGen Pharma over the last few years. It is UroGen Pharma's Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in UroGen Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Cash From Financing Activities | 10 Years Trend |
|
Total Cash From Financing Activities |
| Timeline |
UroGen Total Cash From Financing Activities Regression Statistics
| Arithmetic Mean | 46,611,853 | |
| Coefficient Of Variation | 108.78 | |
| Mean Deviation | 42,129,710 | |
| Median | 21,581,000 | |
| Standard Deviation | 50,703,763 | |
| Sample Variance | 2570.9T | |
| Range | 165.3M | |
| R-Value | 0.70 | |
| Mean Square Error | 1406.1T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 7,953,724 | |
| Total Sum of Squares | 35992.2T |
UroGen Total Cash From Financing Activities History
About UroGen Pharma Financial Statements
UroGen Pharma investors utilize fundamental indicators, such as Total Cash From Financing Activities, to predict how UroGen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Cash From Financing Activities | 116.9 M | 62.6 M |
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against UroGen Stock
| 0.74 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.73 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.69 | BHC | Bausch Health Companies | PairCorr |
| 0.67 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of UroGen Pharma Correlation against competitors. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.